Status
Unknown
Phase
Not applicable
Enrollment
100
Locations
1
Results
Not posted
Publications
0
Study summary
This is a randomized, open label, cohort study, in which a total of 100 patients will be enrolled and randomly assigned to receive bivalirudin or heparin in a 1:1 ratio during short-term intervention of non-infarction related artery for acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention. NACE, MACE, any type of BARC bleeding, stent thrombosis will be evaluated in 30 days and 6 months after recruitment.
The 2017 guideline gives a class IIA recommendation ('should be considered') for complete revascularisation in patients presenting with STEMI and multivessel disease, which is approximately 50% of the STEMI population. Staged multivessel PCI during hospitalization (3-5 days after PPCI) is common in contemporary practice. Patients undergoing primary PCI should receive enhanced antithrombotic therapy, includes DAPT and and parenteral anticoagulant, which caused an increased bleeding risk. In addition, repeated use of heparin in a short time may increase the incidence of HIT. Direct thrombin inhibitor bivalirudin, demonstrated a reduced risk of bleeding and an overall favorable profile including reduced NACE. This is a randomized, open label, cohort study, which is aimed to investigate the safety and efficacy of bivalirudin during short-term intervention of non-infarction related artery for acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention.
Interventions
DRUG
Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
DRUG
Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
Timeline
First posted
Jul 17, 2020
Study start
Jan 12, 2021
Primary completion
Dec 2022
Study completion
Dec 2022
Results posted
Not reported
Registry updated
May 2, 2022
Outcomes
Net adverse clinical events (NACE)
Time frame · 30 days
A composite of major adverse cardiac or cerebral events (all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke) or any bleeding as defined by BARC definition (grades 1-5). BARC=Bleeding Academic Research Consortium
Major adverse cardiac and cerebral events (MACE)
Time frame · 30 days
A composite of all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke
Major adverse cardiac and cerebral events (MACE)
Time frame · 6 months
A composite of all-cause death, reinfarction, ischemia-driven target vessel revascularization, or stroke
Bleeding
Time frame · 30 days
Bleeding as defined by BARC definition (grades 1-5). Bleeding was considered medically actionable if BARC types 2-5 and was considered major if BARC types 3-5 occurred. BARC=Bleeding Academic Research Consortium
Bleeding
Time frame · 6 months
Bleeding as defined by BARC definition (grades 1-5). Bleeding was considered medically actionable if BARC types 2-5 and was considered major if BARC types 3-5 occurred. BARC=Bleeding Academic Research Consortium
Stent thrombosis
Time frame · Hospitalization
Stent thrombosis as defined by ARC ARC=Academic Research Consortium
Stent thrombosis
Time frame · 30 days
Stent thrombosis as defined by ARC ARC=Academic Research Consortium
Stent thrombosis
Time frame · 6 months
Stent thrombosis as defined by ARC ARC=Academic Research Consortium
Eligibility
Inclusion Criteria: * Age ≥ 18 years. * Acute STEMI (including patients within 12 h of symptom onset, or 24-48 h with recurrent or ongoing chest pain chest pain, persistent ST-segment elevation or new left bundle branch block. * Staged intervention of non-infarction related artery within 5 days after PPCI during Hospitalization. * Signed informed consent. Exclusion Criteria: * Cardiogenic shock. * Received thrombolytic therapy or used any anticoagulant drugs within 48 hours before randomized. * Active bleeding, recent bleeding events or bleeding tendency. * History of surgery in the last 1 month. * Suspicious symptoms of aortic dissection, pericarditis and endocarditis. * Blood pressure \> 180/110 mmHg. * Hemoglobin \< 100 g/L, Platelet count \<100×10(9)/L, Transaminase 3 times upper limit of normality or Creatinine clearance \<30ml/min. * History of Heparin-Induced Thrombocytopenia. * Allergic to any research drug or device. * Pregnancy or lactation. * Any condition that makes the patient unsuitable for PCI or may interfere with the study. * Patient disagrees or fails to sign the written informed consent.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Duke University · Coronavirus Infection (COVID-19) · Pulmonary Arterial Hypertension
Not applicable
Recruiting
5,000
2026-07
Sydney Local Health District · Extracorporeal Membrane Oxygenation Complication
Phase 2
Recruiting
80
2026-05
Xiaotong Hou · Extracorporeal Membrane Oxygenation Complication
Not applicable
Recruiting
154
2026-04
Shenyang Northern Hospital · Percutaneous Coronary Intervention · High Bleeding Risk
Phase 4
Not yet recruiting
5,270
2026-02
Stanford University · Heart Failure · Cardiogenic Shock
Phase 2
Recruiting
50
2026-01
NYU Langone Health · Coronary Microvascular Disease · Ischemic Heart Disease
Not applicable
Active, not recruiting
206
2025-11
Shenyang Northern Hospital · ST Elevation Myocardial Infarction
Not applicable
Completed
6,016
2025-08
Peking University First Hospital · Coronary Microvascular Dysfunction
Phase 4
Recruiting
70
2025-08
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.